Skip to main content

Pay Bill Portals

Our Tests
Our Services
- - Oncology
    - - SERVICES
        
        NateraCore Services
        
        Pharma Partnership
    - - FOR PATIENTS
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
        
        Contact Us
    - - FOR CLINICIANS
        
        Schedule Session With Client Services
        
        Oncology Portal
        
        Order a Test Kit
        
        Contact Us
  - Organ Health
    - - SERVICES
        
        NateraCore Services
        
        ProReach
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Contact Us
    - - FOR CLINCIANS
        
        Organ Health Portal
        
        Contact Us
  - Women’s Health
    - - SERVICES
        
        NateraCore Services
        
        Constellation
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Pricing and Billing Information
        
        Women’s Health Portal
        
        Contact Us
    - - FOR CLINICIANS
        
        Order Tests and Track Status on NateraConnect
        
        View Patient Results on NateraConnect
        
        Contact Us
Patient Resources
- - Oncology
    - - LEARN
        
        Signatera
        Altera
        Empower
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
    - - CONNECT
        
        Contact Us
  - Organ Health
    - - LEARN
        
        Prospera
        Renasight
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule a Genetic Information Session
    - - CONNECT
        
        Contact Us
  - Women’s Health
    - - LEARN
        
        Horizon
        Panorama
        Empower
        Vistara
        Anora
        Spectrum
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule a Genetic Information Session
        
        Schedule Blood Draw (Existing Patients)
        
        Pricing and Billing Information
        
        Women’s Health Portal
    - - CONNECT
        
        Contact Us
Clinical Resources
- - Oncology
    - - CLINICAL RESOURCES
        
        Order Forms
        
        Signatera
        Signatera Publications
        Altera
        Empower
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        Signatera Research Pipeline
        
        BESPOKE CRC
        
        BESPOKE IO
    - - CONNECT
        
        Oncology Portal
        
        Contact Us
  - Organ Health
    - - CLINICAL RESOURCES
        
        Organ Health Publications
        Prospera
        Renasight
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        ProActive Study
        
        PEDAL Study
        
        Trifecta Study
        
        MOTR Study
    - - CONNECT
        
        Organ Health Portal
        
        Contact Us
  - Women’s Health
    - - CLINICAL RESOURCES
        
        Women’s Health Publications
        Horizon
        Panorama
        Empower
        Vistara
        Anora
        Spectrum
        Natera Academy Provider Education Hub
        View All Clinician Resources
    - - RESEARCH STUDIES
    - - CONNECT
        
        Contact Us
Company
Search for:
Pay Bill

Portals
Search for:

Natera, Inc.

- Altera
- Anora
- Empower
- Horizon
- Panorama
- Prospera
- Renasight
- Signatera
- Spectrum
- Vistara
- Blog
- Videos
- Brochure
- Whitepaper
- Manual
- Poster
- Report
- Study
- Webinars
- Natera Academy

Recent Searches

Home
Poster
Utility of ctDNA as an Early Predictive Biomarker of Response to RT/CRT in Gynecologic Malignancies

Utility of ctDNA as an Early Predictive Biomarker of Response to RT/CRT in Gynecologic Malignancies

Published Date March 20, 2024

Previous Resource

Treatment Monitoring Utilizing ctDNA-based Molecular Residual Disease Detection in Early Stage Uterine Cancer
Next Resource

Prognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA in patients with ovarian

Related Content

6 months ago
Feasibility of Tumor-Informed Circulating Tumor DNA (ctDNA) for Molecular Residual Disease (MRD) Assessment in Pediatric Patients with Solid

Read More
6 months ago
Personalized circulating tumor (ct)DNA for monitoring disease status in head and neck squamous cell carcinoma

Read More
6 months ago
Longitudinal Analysis of Circulating Tumor DNA in Localized and Metastatic Urothelial Cancer

Read More
6 months ago
Association Between Circulating Tumor DNA and Recurrence-Free Survival in Patients with Resected Stage III Melanoma

Read More
6 months ago
A targeted panel of actionable high risk hereditary cancer predisposition genes can identify patients with pathogenic/likely pathogenic vari

Read More
6 months ago
Longitudinal Evaluation of Circulating Tumor DNA (ctDNA) as a Prognostic Biomarker to Detect Minimal Residual Disease (MRD) in Testicular Ca

Read More
6 months ago
Trial in Progress: Randomized phase III study comparing suspension or continuation of PD-1 Pathway Blockade for patients with advanced non-s

Read More
6 months ago
Abstract # 518: ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1

Read More
6 months ago
Abstract 3598: Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosi

Read More
6 months ago
Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) t

Read More
6 months ago
Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal j

Read More
6 months ago
Genomic alterations in early-onset versus average-onset stage IV colorectal cancer

Read More
6 months ago
Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-ins

Read More
6 months ago
Clinical Validation of a SNP-based Prenatal Cell-free DNA Screening Test for Fetal RHD Status in a Large US Cohort

Read More
9 months ago
Utility of ctDNA in assessment of treatment response in patients with Recurrent/Metastatic Endometrial Cancer and Recurrent/Platinum-Resista

Read More
9 months ago
Personalized circulating tumor DNA analysis used for ctDNA detection and response monitoring in patients with advanced or recurrent uterine

Read More
9 months ago
PARPi response monitoring using personalized circulating tumor DNA testing in patients with ovarian cancer

Read More
9 months ago
Treatment Monitoring Utilizing ctDNA-based Molecular Residual Disease Detection in Early Stage Uterine Cancer

Read More
9 months ago
Prognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA in patients with ovarian

Read More
9 months ago
Diagnostic yield and characteristics of germline-positive genetic testing ordered by obstetricians and gynecologists

Read More

Return to Resource Library

© Natera, Inc.

Our Tests
Our Services
Patient Resources
Clinical Resources
- Resource Library
- Provider Portals
Company
Contact

Natera Licenses
IT Security Compliance
Natera Notice of Data Collection for California Residents
Privacy Practices
Privacy Policy
Terms of Use
Sitemap

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved.